| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1996;94:3168-3175.)
© 1996 American Heart Association, Inc.
Articles |
Myocardial Involvement Is Very Frequent Among Patients Affected With Subclinical Becker's Muscular Dystrophy
the Departments of Cardiology (P.M., C.V., M.M., G.F., S.D.V.), Neurology (M.F., F.M., M.P.F., C.A.), and Biology (G.A.D., M.M., M.L.M.), University of Padua, Padua, Italy.
Correspondence to Dr Paola Melacini, MD, Department of Cardiology, University of Padua, Via Giustiniani 2, 35128 Padua, Italy.
Background Several cases of Becker's muscular dystrophy (BMD) have been reported, which showed mild or subclinical skeletal muscle involvement with an overt dilated cardiomyopathy. Here, for the first time, a group of 28 patients with BMD who had a subclinical or benign myopathy have been studied through a thorough cardiological assessment.
Methods and Results Each patient underwent ECG and echocardiographic examinations. Molecular analyses of the dystrophin gene and protein were performed. An unexpectedly high incidence of myocardial involvement was observed among patients affected with subclinical (72%) or benign (60%) BMD. The cardiac involvement appears to develop early from the right ventricle. Both the increase in left ventricular end-diastolic volume and the reduction in the ejection fraction appeared to be age related. Severe left ventricular dilation with reduced ejection fraction, which could be complicated by life-threatening arrhythmias, may occur. Contrary to previous reports, which indicated the involvement of 5'-end mutations in cardiomyopathies as a result of dystrophin gene alterations, this study shows that despite the apparent concentration of deletions in two regions (5'-end and exons 47 through 49), no general conclusions can be drawn regarding the involvement of specific gene mutations in the development of cardiomyopathy.
Conclusions Cardiomyopathy is the main clinical feature and complication in patients affected by subclinical or mild BMD. The cardiac manifestation is characterized by early right ventricular involvement and is later associated with left ventricular impairment. In mild BMD, myocardial damage may develop because the patients, who are unaware of a possible cardiac involvement, are still able to perform strenuous muscle exercise and, through pressure or volume overload, may induce mechanical stress, which is harmful for dystrophin-deficient myocardial cells.
Key Words: cardiomyopathy • echocardiography • molecular biology • muscles
This article has been cited by other articles:
 |
|
 |
|
  A Y Manzur and F Muntoni Diagnosis and new treatments in muscular dystrophies Postgrad. Med. J., November 1, 2009; 85(1009): 622 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Y Manzur and F Muntoni Diagnosis and new treatments in muscular dystrophies J. Neurol. Neurosurg. Psychiatry, July 1, 2009; 80(7): 706 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Duan Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R253 - R261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Gavillet, J.-S. Rougier, A. A. Domenighetti, R. Behar, C. Boixel, P. Ruchat, H.-A. Lehr, T. Pedrazzini, and H. Abriel Cardiac Sodium Channel Nav1.5 Is Regulated by a Multiprotein Complex Composed of Syntrophins and Dystrophin Circ. Res., August 18, 2006; 99(4): 407 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Jefferies, B. W. Eidem, J. W. Belmont, W. J. Craigen, S. M. Ware, S. D. Fernbach, S. R. Neish, E. O. Smith, and J. A. Towbin Genetic Predictors and Remodeling of Dilated Cardiomyopathy in Muscular Dystrophy Circulation, November 1, 2005; 112(18): 2799 - 2804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Y. Park, Y. Ahn, W. S. Park, J. H. Lim, H. W. Park, J. H. Kim, Y. J. Hong, W. Kim, M. H. Jeong, J. G. Cho, et al. Rapid progression from hypertrophic cardiomyopathy to heart failure in a patient with Becker's muscular dystrophy Eur J Heart Fail, June 1, 2005; 7(4): 684 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Varghese and D J Pennell Late gadolinium enhanced cardiovascular magnetic resonance in Becker muscular dystrophy Heart, September 1, 2004; 90(9): e59 - e59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Cohen and F Muntoni Multiple pathogenetic mechanisms in X linked dilated cardiomyopathy Heart, August 1, 2004; 90(8): 835 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yue, J. W. Skimming, M. Liu, T. Strawn, and D. Duan Full-length dystrophin expression in half of the heart cells ameliorates {beta}-isoproterenol-induced cardiomyopathy in mdx mice Hum. Mol. Genet., August 1, 2004; 13(15): 1669 - 1675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yue, Z. Li, S. Q. Harper, R. L. Davisson, J. S. Chamberlain, and D. Duan Microdystrophin Gene Therapy of Cardiomyopathy Restores Dystrophin-Glycoprotein Complex and Improves Sarcolemma Integrity in the Mdx Mouse Heart Circulation, September 30, 2003; 108(13): 1626 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Saotome, Y. Yoshitomi, S. Kojima, and M. Kuramochi Dilated Cardiomyopathy of Becker-Type Muscular Dystrophy with Exon 4 Deletion: A Case Report Angiology, May 1, 2001; 52(5): 343 - 347. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Arbustini, M. Diegoli, P. Morbini, B. Dal Bello, N. Banchieri, A. Pilotto, F. Magani, M. Grasso, J. Narula, A. Gavazzi, et al. Prevalence and characteristics of dystrophin defects in adult male patients with dilated cardiomyopathy J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1760 - 1768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Badorff, N. Berkely, S. Mehrotra, J. W. Talhouk, R. E. Rhoads, and K. U. Knowlton Enteroviral Protease 2A Directly Cleaves Dystrophin and Is Inhibited by a Dystrophin-based Substrate Analogue J. Biol. Chem., April 6, 2000; 275(15): 11191 - 11197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Beggs Dystrophinopathy, The Expanding Phenotype: Dystrophin Abnormalities in X-Linked Dilated Cardiomyopathy Circulation, May 20, 1997; 95(10): 2344 - 2347. [Full Text]
|
|